Shire Strengthens its Regenerative Medicine Business with Pervasis Therapeutics Purchase

By Heather Cartwright

PharmaDeals Review: Vol 2012 Issue 4 (Table of Contents)

Published: 24 Apr-2012

DOI: 10.3833/pdr.v2012.i4.1730     ISSN: 1756-7874

Section: Mergers & Acquisitions

Fulltext:

Abstract

Shire is to bolster its burgeoning regenerative medicine division by acquiring substantially all of the assets of Pervasis Therapeutics in a deal that is reportedly worth as much as US$200 M...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: PharmaDeals Ltd

Bookmarks

Bookmark PharmaDeals through one of these social networks.